Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The present study was designed as a randomized, single blind, placebo-controlled, study to
evaluate the effect of 400 µg of recombinant human GM-CSF applied intralesionally and
associated with half of the total dose of antimony in a reduced time schedule (20mgSbV/Kg/d
for 10 days) as compared to the full dose of antimony (20mgSbV/Kg/d for 20 days) to treat
cutaneous leishmaniasis ulcers.